AbCellera Biologics Inc. (ABCL)

NASDAQ: ABCL · Real-Time Price · USD
2.040
0.00 (0.00%)
At close: May 29, 2025, 4:00 PM
2.050
+0.010 (0.49%)
After-hours: May 29, 2025, 7:52 PM EDT
0.00%
Market Cap 608.91M
Revenue (ttm) 23.11M
Net Income (ttm) -167.87M
Shares Out 298.48M
EPS (ttm) -0.57
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,635,372
Open 2.060
Previous Close 2.040
Day's Range 2.000 - 2.080
52-Week Range 1.891 - 4.200
Beta 0.46
Analysts Strong Buy
Price Target 8.33 (+308.33%)
Earnings Date May 8, 2025

About ABCL

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Dec 11, 2020
Employees 596
Stock Exchange NASDAQ
Ticker Symbol ABCL
Full Company Profile

Financial Performance

In 2024, AbCellera Biologics's revenue was $28.83 million, a decrease of -24.17% compared to the previous year's $38.03 million. Losses were -$162.86 million, 11.2% more than in 2023.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for ABCL stock is "Strong Buy." The 12-month stock price forecast is $8.33, which is an increase of 308.33% from the latest price.

Price Target
$8.33
(308.33% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause.

15 days ago - Business Wire

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit.

17 days ago - Business Wire

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Presents Positive Preclinical Data on ABCL575 at the SID Annual Meeting 2025.

20 days ago - Business Wire

AbCellera Biologics Inc. (ABCL) Q1 2025 Earnings Call Transcript

AbCellera Biologics Inc. (NASDAQ:ABCL) Q1 2025 Earnings Conference Call May 8, 2025 5:00 PM ET Company Participants Tryn Stimart - Chief Legal and Compliance Officer Carl Hansen - President and Chief...

21 days ago - Seeking Alpha

AbCellera Reports Q1 2025 Business Results

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Q1 2025 Business Results.

21 days ago - Business Wire

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera presents data showing preclinical efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025.

4 weeks ago - Business Wire

AbCellera to Participate at Upcoming Investor Conferences in May and June

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Participate at Upcoming Investor Conferences in May and June.

7 weeks ago - Business Wire

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025.

2 months ago - Business Wire

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025.

2 months ago - Business Wire

AbCellera Biologics Inc. (ABCL) Q4 2024 Earnings Call Transcript

AbCellera Biologics Inc. (NASDAQ:ABCL) Q4 2024 Earnings Conference Call February 27, 2025 5:00 PM ET Company Participants Tryn Stimart - Chief Legal and Compliance Officer Carl Hansen - Chief Executi...

3 months ago - Seeking Alpha

AbCellera Reports Full Year 2024 Business Results

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Full Year 2024 Business Results.

3 months ago - Business Wire

AbCellera to Participate at Upcoming Investor Conferences in March

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Participate at Upcoming Investor Conferences in March.

3 months ago - Business Wire

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Full Year 2024 Financial Results on February 27, 2025.

4 months ago - Business Wire

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology.

4 months ago - Business Wire

AbCellera Biologics: Still A Concept Stock

Today, we revisit a somewhat unique developmental company called AbCellera Biologics Inc. The company is moving towards focusing more on its wholly owned candidates off its platform rather than partne...

5 months ago - Seeking Alpha

AbCellera to Present at Upcoming Investor Conferences in December and January

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at Upcoming Investor Conferences in December and January.

6 months ago - Business Wire

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024.

7 months ago - Business Wire

AbCellera Biologics Inc. (ABCL) Q3 2024 Earnings Call Transcript

AbCellera Biologics Inc. (NASDAQ:ABCL) Q3 2024 Earnings Conference Call November 4, 2024 5:00 PM ET Company Participants Tryn Stimart - Chief Legal and Compliance Officer Carl Hansen - Chief Executiv...

7 months ago - Seeking Alpha

AbCellera Reports Q3 2024 Business Results

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Q3 2024 Business Results.

7 months ago - Business Wire

AbCellera to Present at Upcoming Investor Conferences in November 2024

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at Upcoming Investor Conferences in November 2024.

7 months ago - Business Wire

AbCellera: A Platform To Pipeline Transition

AbCellera is shifting its focus from a platform biotech company to its internal drug pipeline. The company's lead asset, ABCL575, comes with a variety of risks, but in our opinion, has a value of a li...

8 months ago - Seeking Alpha

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024.

8 months ago - Business Wire

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024.

8 months ago - Business Wire

AbCellera to Present at Upcoming Investor Conferences in September

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at Upcoming Investor Conferences in September.

9 months ago - Business Wire

AbCellera: A Waiting Game With High Uncertainty

AbCellera's Q2 2024 revenue declined by 27% year-over-year to $7.3 million. The company's net loss widened to $36.9 million due to increased R&D expenses. AbCellera's cash and marketable securities to...

9 months ago - Seeking Alpha